GPER/GPR30 Antibody

Western Blot: GPER/GPR30 Antibody [NBP1-31239] -

Western Blot: GPER/GPR30 Antibody [NBP1-31239] - AhR & GPR30 receptors are present & functional in the MCF10AT1 cells. (A) RT-qPCR analysis of AhR & GPR30 mRNA expression levels represented in arbitrary units (a.u.) in the MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. Values represent mean ± SD of three independent experiments conducted in triplicate. (B) Representative Western blot analyses from three independent experiments of AhR & GPR30 protein expression in MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. (C) XRE-luciferase activity following 8 h exposure of MCF10AT1 cells to ITE at the indicated concentrations. TCDD 10−7 M was used as a control & results were expressed as % of TCDD 10−7 M activity. ***p < 0.001 in Student t-test. (D) XRE-luciferase activity upon 8 h of exposure to ITE 10−10 M alone or in combination with GNF351 at the indicated concentrations. TCDD 10−7 M was used as a control, & results were expressed as % of TCDD 10−7 M activity. Student t-tests revealed the statistically significant differences between unexposed & exposed cells: ***p < 0.001; & between ITE & ITE+GNF351: ###p < 0.001. Values in (C,D) represent mean ± SD of three independent experiments. (E) Representative Western blot analyses from three independent experiments of the phospho-MAPK/MAPK ratio upon exposure of MCF10AT1 cells to G1 (GPR30 agonist) for the times indicated, in the presence or absence of a 2 h pre-treatment with G15 (GPR30 antagonist). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GPER/GPR30 Antibody [NBP1-31239] -

Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GPER/GPR30 Antibody [NBP1-31239] -

Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Human endothelial cells express GPR30 protein in the cell nucleus.(A) Confluent monolayers of HUVECs from 3 different cords were lysed & the protein lysates were immunoblotted for GPR30. alpha-tubulin was used as loading control. (B) HUVEC monolayers at 30–40% confluence were treated with 40 nM siRNA (control or GPR30_4) for 48 hours prior to lysis followed by immunoblotting of the cell lysates for GPR30. alpha-tubulin was used as loading control. Data shown are mean ± SEM of 4 independent experiments. ** & ## indicate p<0.01 compared to untreated & control siRNA-treated cells, respectively. (C) Confluent HUVECs grown on glass coverslips were fixed, permeabilized & immunostained with anti-GPR30 antibody. Nuclei were stained with Hoechst33342 dye. The merged image shows GPR30 (red) & nuclei (blue) in pseudocolor. Representative images from 3 independent experiments are shown. Bar, 20 µm. (D) Confluent HUVECs were lysed & fractionated into cytosolic (C) & nuclear (N) fractions prior to western blotting for eNOS, GPR30, p65, alpha-tubulin & c-Jun. A representative set of images (obtained from different membranes) from 3 independent experiments is shown. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/23285008), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GPER/GPR30 Antibody [NBP1-31239] -

Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GPER/GPR30 Antibody [NBP1-31239] -

Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.